Home Health Drug developer Servier’s brain cancer drug slows tumor progession considerably

Drug developer Servier’s brain cancer drug slows tumor progession considerably

2 min read

Web Desk, June 5, 2023: Private drug developer Servier Group said its experimental brain cancer treatment has considerably slowed the progession of a type of brain tumor, a positive in a field that has not seen progress for more than 20 years.

The drug, vorasidenib, delayed the growth of grade 2 glioma for a median of 27.7 months, more than twice compared to 11.1 months for patients who received a placebo.

Grade 2 gliomas are progressive, malignant brain tumors, which are more common in adults but can also occur in children and teenagers.

The study, involving 331 patients who had undergone no previous treatment other than surgery, showed that vorasidenib significantly improved progression-free survival and delayed the time before moving to further anticancer intervention like chemotherapy and radiation, according to results that have also been published in the New England Journal of Medicine.

Vorasidenib was granted fast track designation by the U.S. Food & Drug Administration (FDA) in March 2023 and the company is currently working on timelines for submission of a New Drug Application (NDA) for vorasidenib to the FDA.

The drug was a part of French-headquartered Servier’s acquisition of Agios Pharmaceuticals Inc’s cancer business for about $2 billion in 2020.


  • ABC News is an emerging news agency providing timely reports, in-depth analysis, and an unparalleled combination of information relating to Pakistan, China and rest of the world at a single platform.

Spread the love
Load More Related Articles
Load More By Editor in Chief
Load More In Health
Comments are closed.

Check Also

Gigi Hadid reacts to Zayn Malik’s photo

Web Desk, July 25, 2023: Gigi Hadid on Monday surprised her fans when she showed subtle su…